Anadolu Medical Center
Anadolu Medical Center
Turcja, Stambuł
Sinan Karaaslan
29 lat doświadczenia
akredytacje :
Akredytacje :
Koszt immunoterapii raka piersi w Turcji wynosi zazwyczaj od $9,500 do $17,500. Ostateczna cena zależy od schematu leczenia, liczby cykli oraz podtypu nowotworu, na przykład raka potrójnie ujemnego. W Polsce podobne procedury kosztują średnio około $30,000. Turcja oferuje oszczędności rzędu 55%. Programy najczęściej obejmują konsultacje specjalistyczne, wlewy dożylne oraz podstawowe badania laboratoryjne.
Opinia ekspercka Bookimed: Wybór placówek z akredytacją JCI, takich jak Anadolu Medical Center czy Memorial Şişli, gwarantuje dostęp do protokołów na poziomie Johns Hopkins. Pacjenci korzystają z opieki lekarzy certyfikowanych przez ESMO, takich jak dr Yesim Yildirim lub dr Seref Komurcu. Specjaliści ci przyjmują rocznie ponad 65 000 pacjentów. Dzięki tak dużej liczbie przypadków kliniki oferują nowoczesne terapie, jak Keytruda, w trybie ambulatoryjnym, co obniża koszty leczenia.
Dlaczego pacjenci wybierają Turcję na immunoterapię raka piersi?
Skorzystaj z zaawansowanych rozwiązań immunoterapii raka piersi w zaufanych klinikach .
| Turcja | Austria | Hiszpania | |
| Immunoterapia raka piersi | od $9,500 | od $35,000 | od $45,000 |
Day 1 - Arrival
Day 2 - Pre-Operation
Day 3 - Immunotherapy
Day 4 - Post-Operation
Week 1 to Week 3 - Rehabilitation
Week 4 to Week 6 - Rehabilitation
Please note that each patient reacts differently to immunotherapy. Therefore, this guide might not perfectly correspond to your individual journey. Always consult with your medical team for personalized information.
Dr Bülent Karagöz jest doświadczonym tureckim onkologiem, specjalistą od mięsaków i chłoniaków oraz chirurgiem raka piersi z ponad 20-letnim doświadczeniem. Posiada wiedzę specjalistyczną w zakresie biologii nowotworów, immunologii nowotworów, immunoterapii nowotworów i terapii ukierunkowanych. Napisał ponad 40 publikacji na temat badań nad rakiem i jest członkiem Turkish Medical Oncology Association.
Dr Eda Tanrikulu specjalizuje się w onkologii klinicznej i chemioterapii w Centrum Medycznym Anadolu, ze szczególnym uwzględnieniem immunoterapii raka piersi.
Dr Solak specjalizuje się w leczeniu raka piersi, posiadając staż specjalizacyjny w Instytucie Onkologii Uniwersytetu Hacettepe – jednym z wiodących ośrodków onkologicznych w Turcji.
Prof. Sezer Sağlam specjalizuje się w onkologii medycznej z naciskiem na immunoterapię raka piersi w Szpitalu Florence Nightingale w Gayrettepe.
Immunotherapy in Turkey primarily treats triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen, progesterone, and HER2 receptors. Specialized oncology centers like Anadolu Medical Center and Memorial Şişli Hospital utilize immune checkpoint inhibitors for early-stage high-risk cases and metastatic tumors expressing the PD-L1 biomarker.
Bookimed Expert Insight: The $9,500 to $17,500 cost range often reflects Turkey's shift toward the KEYNOTE-522 regimen. This protocol requires long-term coordination between surgeons and oncologists. Centers like Anadolu Medical Center maintain a strategic partnership with Johns Hopkins Medicine. This ensures patients receive US-standard care while paying locally competitive rates.
Patient Consensus: Patients emphasize the importance of early PD-L1 testing to determine eligibility. Many report significant practical relief from the seamless coordination provided by dedicated international patient departments and professional translators.
Turkish hospitals provide advanced immunotherapy drugs identical to FDA and EMA-approved protocols. Primary options include immune checkpoint inhibitors like pembrolizumab and atezolizumab, alongside monoclonal antibodies such as trastuzumab and pertuzumab. Specialized centers like Anadolu Medical Center and Medipol Bahçelievler Hospital deliver these therapies using international oncology standards.
Bookimed Expert Insight: Patients can access U.S.-aligned treatment protocols at centers like Anadolu Medical Center due to its strategic partnership with Johns Hopkins Medicine. Our data shows that top Turkish oncologists often hold ESMO certifications and have published over 80 peer-reviewed papers on immunotherapy. This high level of specialization ensures that complex drug combinations are managed with the same expertise found in leading Western institutions.
Patient Consensus: Patients report significant cost advantages, with infusions at private hospitals costing roughly $5,000 compared to $12,000 in the U.S. Reliability is highest at private international hubs, where English-speaking coordinators manage the entire treatment timeline seamlessly.
Immunotherapy success rates for breast cancer in Turkey align with global clinical standards, showing response rates between 20% and 50% for advanced triple-negative cases. Outcomes improve significantly when combined with chemotherapy, particularly in patients testing positive for specific biomarkers like PD-L1 or high tumor mutational burden.
Bookimed Expert Insight: Anadolu Medical Center stands out because its protocols literally mirror Johns Hopkins Medicine standards. Professors like Bulent Karagoz and Yesim Yildirim bring US and European board certifications to the table. This clinical alignment often gives patients access to precision medicine usually reserved for top-tier Western university hospitals.
Patient Consensus: Patients emphasize that early biomarker testing for PD-L1 is vital to avoid ineffective treatments. Many report feeling safer in facilities where multilingual coordinators and translators manage every step of the diagnostic process.
Top hospitals for immunotherapy in Turkey include Anadolu Medical Center, Memorial Şişli Hospital, and Medipol Mega University Hospital. these JCI-accredited facilities offer advanced protocols like Keytruda and CAR-T cell therapy. They feature experts like Dr. Bulent Karagoz and Dr. Yesim Yildirim who follow international oncology standards.
Bookimed Expert Insight: Anadolu Medical Center stands out because its specialists follow strict U.S. protocols through a strategic collaboration with Johns Hopkins Medicine. Dr. Bulent Karagoz and his team have published over 40 peer-reviewed papers on tumor biology. This academic focus ensures patients receive research-backed immunotherapy regimens equivalent to top American centers.
Patient Consensus: Patients value the meticulous organization and professional support from coordinators. They often highlight feeling safe and well-informed throughout complex diagnostic and treatment stages.